163 related articles for article (PubMed ID: 38342997)
41. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.
Yu H; Wang C; Lei Y; Li L; Wang H; Wang G; Xing L; Guan J; Song J; Wu Y; Liu H; Qu W; Wang X; Shao Z; Fu R
Int Immunopharmacol; 2024 Jan; 127():111232. PubMed ID: 38091830
[TBL] [Abstract][Full Text] [Related]
42. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract][Full Text] [Related]
43. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
44. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
45. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
46.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
47. Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Vachhani P; Flahavan EM; Xu T; Ma E; Montez M; Gershon A; Onishi M; Jin H; Ku G; Flores B; Bui CN; Abbas JA; Donnellan W
Oncologist; 2022 Nov; 27(11):907-918. PubMed ID: 35925602
[TBL] [Abstract][Full Text] [Related]
48. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.
Chua CC; Hammond D; Kent A; Tiong IS; Konopleva MY; Pollyea DA; DiNardo CD; Wei AH
Blood Adv; 2022 Jul; 6(13):3879-3883. PubMed ID: 35511730
[TBL] [Abstract][Full Text] [Related]
49. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
50. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
51. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
[TBL] [Abstract][Full Text] [Related]
52. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Gangat N; Tefferi A
Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
[TBL] [Abstract][Full Text] [Related]
53. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Qin Y; Kuang P; Liu T
Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
55. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M; Menghrajani K; Derkach A; Chan A; Xiao W; Glass J; King AC; Daniyan AF; Famulare C; Cuello BM; Horvat TZ; Abdel-Wahab O; Levine RL; Viny AD; Stein EM; Cai SF; Roshal M; Tallman MS; Goldberg AD
Blood Adv; 2021 Mar; 5(5):1552-1564. PubMed ID: 33687434
[TBL] [Abstract][Full Text] [Related]
56. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
[TBL] [Abstract][Full Text] [Related]
57. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients.
Zong L; Yin M; Kong J; Zhang J; Song B; Zhu J; Xue S; Wu X; Wu D; Bao X; Qiu H
Mol Carcinog; 2023 Oct; 62(10):1572-1584. PubMed ID: 37555764
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
59. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract][Full Text] [Related]
60. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
